BRAF mutations can result in the continuous activation of the MAPK/ERK pathway, even in the absence of growth factors. This persistent signaling promotes cell proliferation and survival, leading to tumor formation. The most common mutation, V600E, substitutes valine (V) with glutamic acid (E) at position 600, making the BRAF protein constitutively active.
